Hudson Bay Capital Management
NAVB

Hudson Bay Capital Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Hudson Bay Capital Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,110
Closed -$3K – 1402
2022
Q3 		$3K Buy
+11,110
New +$5.18K ﹤0.01% 1188

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hudson Bay Capital Management's NAVB Position: Q4 2022 in Review

Hudson Bay Capital Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2022, closing a stake of 11,110 shares — an estimated $3K sold.

Hudson Bay Capital Management first reported a position in NAVB in Q3 2022 and held it in 1 quarter. The position peaked at $3K in Q3 2022. 28 funds tracked by Wall St. Rank hold NAVB as of Q4 2022.

  • Hudson Bay Capital Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2022 after selling out during the quarter.
  • Hudson Bay Capital Management sold 11,110 Navidea Biopharmaceuticals Inc. shares in Q4 2022, an estimated $3K.
  • Hudson Bay Capital Management first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2022 and held it in 1 quarter.
  • Hudson Bay Capital Management's Navidea Biopharmaceuticals Inc. position peaked at $3K in Q3 2022.
  • 28 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2022.

Based on Hudson Bay Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.